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Abstract  
Recent genetic studies have identified some alleles associated with higher BMI but lower risk 
of type 2 diabetes, hypertension and heart disease. These “favorable adiposity” alleles are 
collectively associated with lower insulin levels and higher subcutaneous-to-visceral adipose 
tissue ratio and may protect from disease through higher adipose storage capacity. We aimed 
to use data from 164,609 individuals from the UK Biobank and five other studies to replicate 
associations between a genetic score of 11 favorable adiposity variants and adiposity and risk 
of disease, test for interactions between BMI and favorable adiposity genetics and test effects 
separately in men and women.  
In the UK Biobank the 50% of individuals carrying the most favorable adiposity alleles had 
higher BMIs (0.120 Kg/m
2 
[0.066,0.174]; p=1E-5) and higher body fat percentage (0.301 % 
[0.230,0.372]; p=1E-16) compared to the 50% of individuals carrying the fewest alleles. For 
a given BMI, the 50% of individuals carrying the most favourable adiposity alleles were at: 
0.837 OR [0.784,0.894] lower risk of type 2 diabetes (p=1E-7), -0.859 mmHg [-1.099,-0.618] 
lower systolic (p=3E-12) and -0.394 mmHg [-0.534,-0.254] lower diastolic blood pressure 
(p=4E-8), 0.935 OR [0.911,0.958] lower risk of hypertension (p=1E-7) and 0.921 OR 
[0.872,0.973] lower risk of heart disease (p=3E-3). In women, these associations could be 
explained by the observation that the alleles associated with higher BMI but lower risk of 
disease were also associated with a favourable body fat distribution, with a lower waist-hip 
ratio (-0.004 [-0.005,-0.003] 50% vs 50%; p=3E-14) but in men, the favourable adiposity 
alleles were associated with higher waist circumference (0.454 cm [0.267,0.641] 50% vs 
50%; p=2E-6) and higher waist-hip ratio (0.0013 [0.0003,0.0024] 50% vs 50%; p=0.01). 
Results were strengthened when meta-analysing with five additional studies. There was no 
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evidence of interaction between a genetic score consisting of known BMI variants and the 
favorable adiposity genetic score.  
In conclusion, different molecular mechanisms that lead to higher body fat percentage (with 
greater subcutaneous storage capacity) can have different impacts on cardiometabolic disease 
risk. While higher BMI is associated with higher risk of diseases, better fat storage capacity 
could reduce the risk.  
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Introduction 
Some obese individuals are metabolically healthy whilst some normal weight individuals 
have an elevated risk of type 2 diabetes, heart disease and hypertension (1; 2). One of the 
many factors that mean two people of similar BMI can have very different risks of 
cardiometabolic disease is the capacity of subcutaneous adipose tissue to store excess lipids. 
The “adipose tissue expandability” hypothesis states that when adipose tissue stops 
expanding by cell size or number, with continued weight gain the lipid accumulates 
preferentially in ectopic sites such as cardiac, liver and beta cells which can lead to heart 
disease, hypertension, insulin resistance and type 2 diabetes (3). Single gene studies of 
extreme forms of obesity and lipodystrophy, two apparently opposite conditions, support the 
“adipose tissue expandability” hypothesis (4; 5). 
Studies of the general population show that most common genetic variants associated with 
higher BMI are associated with higher risk of type 2 diabetes, hypertension and heart disease, 
either individually as in the case of the variant in the FTO gene (6), or as a genetic risk score 
(7). However, recent studies have also identified common genetic variants where alleles 
associated with lower insulin resistance (8) are also associated with higher BMI and body fat 
percentage and lower risk of type 2 diabetes, hypertension and heart disease (9-11). These 
variants include those in the IRS1 gene, where the common allele associated with higher body 
fat percentage is associated with lower fasting insulin, triglyceride and LDL-cholesterol 
levels, lower insulin secretion and higher insulin sensitivity, adiponectin, HDL-cholesterol 
and leptin levels (9). A genetic score of ten (11) or eleven (10) alleles including that near 
IRS1 had a similar profile with the alleles associated with higher BMI also being associated 
with lower circulating levels of triglyceride and fatty liver markers but higher adiponectin, 
HDL-cholesterol and SHBG levels and lower risk of type 2 diabetes, hypertension and heart 
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disease. These “favorable adiposity” alleles were also associated collectively with a higher 
subcutaneous-to-visceral adipose tissue ratio (10) and higher body fat mass (11), and may 
protect from disease by increasing the capacity of subcutaneous adipose tissue to store excess 
calories as lipids (10). These observations suggest that different molecular mechanisms that 
lead to higher BMI and higher body fat percentage can have different impacts on metabolic 
disease, some of which are paradoxical to epidemiological correlations.  
In this study we had three aims. First, to replicate the association of a genetic score of 11 
favorable adiposity variants (10) with higher BMI and body fat percentage, but lower risk of 
the three diseases of the “metabolic syndrome” - type 2 diabetes, hypertension and heart 
disease. Given the apparently paradoxical associations between higher BMI and lower risk of 
disease we wanted to replicate the effects in large studies not part of previous genome wide 
association study meta-analyses to both confirm associations and establish their true effects in 
population-based studies. Second, to test if a genetic score of favorable adiposity variants 
interacted with a genetic score of variants identified as associated primarily with BMI. 
Identifying interactions between genetic variants has proven very difficult, but the availability 
of individual level data in the UK Biobank provides an opportunity to identify individuals 
who may be at especially high or low genetic risk of disease if they carry certain 
combinations of alleles. These BMI variants consisted of those recently identified as 
associated with BMI in a meta-analysis of 250,000 individuals (12). Third, we aimed to test 
the role of the favorable adiposity alleles in disease predisposition in men and women 
separately given the differences in body fat distribution between the two sexes. We used the 
UK Biobank study to address these questions because it is a single large relatively 
homogeneous population based study. We used five additional studies not part of previous 
GWA studies to provide additional statistical confidence of our findings. 
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Methods  
Study samples 
All details of the UK Biobank and 5 additional studies are given in table S1. 
The UK Biobank: The UK Biobank recruited over 500,000 individuals aged 37-73 years 
(99.5% were between 40 and 69 years) in 2006-2010 from across the UK. Participants 
provided a range of information via questionnaires and interviews (e.g. demographics, health 
status, lifestyle) and anthropometric measurements, blood pressure readings, blood, urine and 
saliva samples were taken for future analysis; this has been described in more detail 
elsewhere (13). We used 120,286 individuals of British descent from the initial UK Biobank 
dataset. We did not include other ethnic groups, because individually they were 
underpowered to detect previously reported effects. British-descent was defined as 
individuals who both self-identified as white British and were confirmed as ancestrally 
Caucasian using principal components analyses (PCA) of genome wide genetic information. 
This dataset underwent extensive central quality control including the exclusion of the 
majority of third degree or closer relatives from a genetic kinship analysis of 96% of 
individuals. We performed an additional round of principal components analysis (PCA) on 
these 120,286 UK Biobank participants. We selected 95,535 independent SNPs (pairwise r2 
<0.1) directly genotyped with a minor allele frequency (MAF) ≥ 2.5% and missingness 
<1.5% across all UK Biobank participants with genetic data available at the time of this study 
(N=152,732), and with HWE P>1x10-6 within the white British participants. Principal 
components were subsequently generated using FlashPCA (14). 
Additional studies: To provide further evidence for the role of favorable adiposity alleles we 
used a total of 50,753 individuals from 5 studies: EXTEND (6,504 individuals of white 
European descent collected from South West England), GoDARTS (4086 individuals of 
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white European descent collected from North Scotland) (15), Generation Scotland: Scottish 
Family Health Study (14,064 individuals of white European descent collected from Scotland) 
(16), PROSPER (5,244 individuals of white European descent collected from Scotland, 
Ireland and the Netherlands) (17; 18) and EPIC-Norfolk (20,855 individuals of white 
European descent collected from Norfolk) (19). We chose these studies because they were 
not part of the published GWAS used in previous studies (10).  
Phenotypes 
Measures of adiposity 
The UK Biobank: We used BMI and bio-impedance measures of body fat percentage 
measured by the Tanita BC418MA body composition analyser.  
We used body fat percentage as it is a more accurate measure of body composition. The UK 
Biobank provided two measures of BMI – one calculated from weight(kg)/height(m)2 and 
one using height and electrical impedance to quantify mass. We excluded individuals 
(N=1,172 out of 500,000) with differences >4.56 SDs between impedance and normal BMI 
measures where both variables were available (94% of data). If only one measure of BMI was 
available this was used (N=7,290).  
Additional studies: We used BMI and body fat percentage as measures of adiposity. Body fat 
percentage was measured using Tanita digital scale in EXTEND, bio-impedance on a Tanita 
digital scale in Generation Scotland and Tanita digital scale in EPIC-Norfolk. 
Measures of disease and disease related traits. 
The UK Biobank: We used 3 cardiometabolic disease outcomes: type 2 diabetes, 
hypertension (also represented by continuous measures of systolic and diastolic blood 
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pressure) and heart disease – all using baseline data and following similar definitions to those 
used in previous genome wide association studies. 
We defined type 2 diabetes using baseline data and following similar definitions to those used 
in previous genome wide association studies. We defined type 2 diabetes cases if 3 criteria 
were present: i) reports of either type 2 diabetes or generic diabetes at the interview, ii) at 
least one year gap from diagnosis without requiring insulin iii) reported age at diagnosis over 
the age of 35 years to limit the numbers of individuals with slow-progressing autoimmune 
diabetes or monogenic forms. Individuals not reporting an age of diagnosis were excluded. 
We also excluded individuals diagnosed with diabetes within the year prior to the baseline 
study visit as we were unable to determine whether they were using insulin within the first 
year. Controls were individuals not fulfilling these criteria. 
We defined hypertensive cases as individuals with systolic blood pressure of >140 mmHg, or 
a diastolic blood pressure of >90 mmHg, or the report of blood pressure medication usage. 
Controls were individuals not fulfilling these criteria. For the analysis of systolic and diastolic 
blood pressure, we corrected blood pressure measures in people on antihypertensive drugs by 
adding 15 mmHg to systolic and 10 mmHg to diastolic blood pressure, in keeping with the 
approach taken by genome wide association studies. As a sensitivity analysis, we used blood 
pressure measures in individuals who were not on blood pressure medications. 
We defined heart disease cases if individuals reported angina and/or a heart attack at the 
interview stage. We defined Controls as individuals without these conditions. As a sensitivity 
analysis, we used heart disease cases as only those with heart attack at the interview stage. 
Additional studies: We used 3 metabolic disease outcomes: type 2 diabetes, hypertension 
(also represented by continuous measures of systolic and diastolic blood pressure) and heart 
disease. 
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EXTEND defined  type 2 diabetes as self-reported or having  HbA1c >6.4% and excluded in 
case subjects, 1) individuals aged at diagnosis <35 or >70 years; 2) individuals who needed 
insulin treatment within 1 year of diagnosis; and 3) individuals aged <45 years whose age at 
diagnosis was not known at the time of study; and in control subjects, 1) individuals aged <35 
or >70 years at the time of study; and 2) individuals with HbA1c >6.4%. Hypertension and 
heart disease were self-reported. 
GoDARTS defined Diabetes as status at recruitment (case/control). Hypertensive cases were 
defined as individuals with systolic blood pressure of >140 mmHg, or a diastolic blood 
pressure of > 90 mmHg at recruitment. Blood pressure was corrected by adding 15 mmHg to 
systolic and 10 mmHg to diastolic blood pressure in hypertensive cases if they were on blood 
pressure medications. 
Generation Scotland defined Diabetes cases by identifying linkage to prescribing data where 
drugs prescribed were in BNF code group 6.1. The prescriptions were also used to show 
which participants were taking blood pressure lowering drugs (BNF code 2.4, 2.5, 2.6). 
Blood pressure was measured twice during a clinic visit and the mean systolic and diastolic 
values used. Diabetes, hypertension and heart disease were self-reported on a questionnaire at 
the time of participation. 
PROSPER defined type 2 diabetes by (i) known type 2 diabetes, and/or (ii) fasting glucose 
>=7mmol/L, and/or (iii) use of antidiabetic drugs (any oral hypoglycaemic agent or insulin). 
Hypertensive cases were defined as those on use of antihypertensive medication. They 
defined heart disease as combination of prevalent (baseline history of myocardial infarction, 
CABG/PTCA, angina) and incident (coronary heart disease death (definite plus suspect), 
non-fatal myocardial infarction (definite plus suspect), CABG/PTCA) events. All endpoints 
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were validated by a blinded events committee. For detailed end point definitions, please see 
appendix B in (18). 
EPIC-Norfolk used both prevalent and incident type 2 diabetes to define type 2 diabetes 
cases. They used treatment-adjusted variables for systolic and diastolic blood pressure, and 
blood pressure medication to define hypertension. They defined heart disease as self-reported 
myocardial infarction at baseline and incident myocardial infarction. 
Selection of Genetic variants associated with favorable adiposity  
We chose 11 variants previously identified by a hierarchical clustering approach as sharing 
features of monogenic lipodystrophic insulin resistance, including a surrogate measure of 
insulin resistance, subcutaneous to visceral adipose tissue ratio from CT scans, lipids, 
markers of fatty liver disease, and adiponectin (table S2) (10). We refer to the BMI raising 
alleles as “favorable adiposity” alleles throughout the manuscript. 
Selection of Genetic variants associated with BMI  
We selected 69 variants as associated with BMI and refer to the BMI raising alleles as “BMI” 
alleles throughout the manuscript. These 69 were selected from 76 common genetic variants 
associated with BMI at genome wide significance in the Genetic Investigation of 
ANthropometric Traits (GIANT) consortium studies of up to 339,224 individuals (table S3) 
(12). We limited the BMI SNPs to those that were associated with BMI in the analysis of all 
European ancestry individuals and did not include those that only reached genome-wide 
levels of statistical confidence in one-sex only, or one-strata only. Variants were also 
excluded if classified as a secondary signal within a locus. Three SNPs were excluded due to 
potential pleiotropy (rs11030104 (BDNF reward phenotypes), rs13107325 (SLC39A8 lipids, 
blood pressure), rs3888190 (SH2B1 multiple traits)), 3 SNPs were not in Hardy-Weinberg 
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Equilibrium (HWE) (rs17001654, rs2075650, rs9925964) and one SNP was unavailable 
(rs2033529) (table S3).  
Genotypes 
The UK Biobank: We extracted genotypes from UK Biobank’s imputation dataset and used 
genotype dosage values prior to association testing. Individual genotypes were excluded if 
HWE P<E-6 or if imputation quality <0.9. We confirmed that the 11 favorable adiposity 
variants and the 69 BMI variants were imputed with high quality by comparing to the directly 
genotyped data, available in 120,286 UK Biobank individuals of genetically confirmed 
British ancestry. Details of imputation quality are given in tables S2 and S3.  
Additional studies: Table S4 describes the imputation/genotyping methods used by each 
study. 
Genetic score analysis 
We constructed 2 genetic scores: (i) the genetic score of 11 favorable adiposity variants was 
the number of favorable adiposity alleles carried by each individual weighted based on their 
effect on fasting insulin, (ii) the genetic score of 69 BMI variants was the number of alleles 
associated with higher BMI carried by each individual. As a sensitivity analysis, we 
conducted a genetic score of favorable adiposity based on variants that were individually 
associated with body fat percentage in the UK Biobank study. 
Statistical analysis 
For the analysis of individual variants we assumed an additive model. We used 5 covariates 
including age, sex, genotyping platform (two were used), study centre and five within UK 
genetic principle components. As smoking has a big effect on BMI, we ran a sensitivity 
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analysis using smoking as a covariate in the UK Biobank data in addition to the above 
covariates. 
We used the genetic risk score for BMI in order to test the hypothesis that a general genetic 
predisposition to higher BMI interacted with a general predisposition to favorable adiposity. 
We did not investigate specific variants for interaction.  For this interaction analysis between 
two genetic scores (69 BMI variants and 11 favorable adiposity variants) and measures of 
blood pressure and cardiometabolic disease risk, we included the respective interaction terms 
in the models (e.g. interaction term = BMI genetic score x favorable adiposity genetic score. 
Meta-analysis 
We meta-analysed results across the 6 studies using fixed-effects inverse variance-weighted 
meta-analysis. We tested for any evidence of heterogeneity between the results using the 
Cochran Q test. 
Sex dichotomized analysis 
To assess whether or not associations differed between sexes, we repeated the inverse-
variance meta-analyses in men and women separately in the UK Biobank study. Sex-
difference P values were calculated by the Cochran Q test.  
Assessing disease risk in individuals with a genetic susceptibility to high BMI. 
To provide additional context for the interaction analysis, we dichotomized the 11 favorable 
adiposity genetic score and the BMI genetic score into two groups based on the median of the 
two genetic score distributions. We considered individuals with above median favorable 
adiposity genetic score and below median BMI genetic score as having the lowest 
cardiometabolic disease risk and used them as a reference group. By comparing to the 
Page 13 of 58 Diabetes
reference group, we tested blood pressure and the risk of type 2 diabetes, hypertension and 
heart disease in 3 groups of individuals based on the two genetic score distributions: i) those 
at below median of the favorable adiposity genetic score and below median of the BMI 
genetic score, ii) those at above median of the favorable adiposity genetic score and above 
median of the BMI genetic score, and iii) those at below median of the favorable adiposity 
genetic score and above median of the BMI genetic score.   
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Results 
A genetic score of 11 favorable adiposity variants was associated with higher BMI and 
body fat percentage in the UK Biobank. 
The genetic score of 11 favorable adiposity variants was associated with higher body fat 
percentage and higher BMI in the UK Biobank with very high levels of statistical confidence. 
Each additional favourable adiposity weighted allele was associated with a 0.126% 
([0.104,0.149]; p=8E-28) higher fat percentage and 0.046 Kg/m
2
 ([0.029,0.063]; p=2E-7) 
higher BMI. These effects meant that the 50% of people carrying the most favourable 
adiposity alleles had on average 0.301 % ([0.230,0.372]; p=1E-16) additional adipose tissue 
and were 0.120 Kg/m
2 
([0.066,0.174]; p=1E-5) heavier than the 50% of people carrying the 
fewest favourable adiposity alleles (figure 1a). The 11 variants in a multivariable analysis 
explained 0.04% variance in BMI levels and 0.2% variance in body fat percentage in the UK 
Biobank study (N=119,688) after correcting for age, sex, genotyping array, study centre and 
within UK principle components. The analysis of the favorable adiposity genetic score 
against absolute measures of body fat mass and body fat-free mass showed that the effect of 
the 11 favorable adiposity variants was driven by fat-mass not fat-free mass and the genetic 
score was not associated with height (figure 1a; table 1). The genetic score effects were 
predominantly driven by 7 of the 11 variants that were individually associated with body fat 
percentage at p<3E-5 – those in or near the LYPLAL1, PPARG, PEPD, GRB14, IRS1, 
ANKRD55 and FAM13A genes (table S5)    
A genetic score of 11 favorable adiposity variants was associated with lower waist 
circumference and waist-hip ratio in women, but higher waist circumference and waist hip 
ratio in men. 
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In the UK Biobank, the genetic score of 11 favorable adiposity variants associated with 
higher BMI was associated with a favourable body fat distribution, as measured by a lower 
waist-hip ratio (-0.0006 [-0.0009, -0.0004] per allele; p=2E-7) but these effects were 
dichotomised by sex. In women, the alleles associated with higher BMI were also associated 
with a lower waist-hip ratio (-0.0017 [-0.0021, -0.0014] per allele; p=9E-23), an effect driven 
by a larger hip circumference (0.16 [0.11, 0.21] per allele; p=1E-9), with little effect on waist 
circumference (-0.04 [-0.10, 0.02] per allele; p=0.2). In men, the favourable adiposity genetic 
risk score associated with higher BMI was associated with higher waist circumference (0.17 
[0.11, 0.23] per allele; p=1E-8), higher hip circumference (0.12 [0.08, 0.16] per allele; p=1E-
8) and slightly higher waist-hip ratio (0.0005 [0.0002, 0.0009] per allele; p=0.001) (table S6). 
These effects meant that the 50% of men carrying the most favourable adiposity alleles had a 
waist circumference 0.45 cm larger ([0.267,0.641]; p=2E-6) than the 50% of men carrying 
the fewest favourable adiposity alleles. These associations were consistent when meta-
analysing the UK Biobank data with 3 additional studies (figure 2). These effects were even 
stronger when limiting the favorable adiposity genetic score to the 7 variants that were 
individually associated with body fat percentage at p<3E-5 – those in or near the LYPLAL1, 
PPARG, PEPD, GRB14, IRS1, ANKRD55 and FAM13A genes (table S6).    
A genetic score of 11 favorable adiposity variants was associated with lower risk of type 2 
diabetes.  
Despite being associated with higher fat mass, each additional favourable adiposity weighted 
allele was associated with a 0.943 OR ([0.924,0.963]; p=2E-8) lower risk of type 2 diabetes 
in the UK Biobank. This association was statistically stronger when meta-analysing the UK 
Biobank data with five additional studies (table S7). These effects meant that the 50% of 
people carrying the most favourable adiposity alleles had a 0.895 OR ([0.840,0.954]; p=6E-4) 
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lower risk of type 2 diabetes than the 50% of people carrying the fewest favourable adiposity 
alleles (figure 1b; table S8). Despite the dichotomised body fat distribution, these effects 
were consistent in men and women (table S9) and across 6 different bands of BMI (<25,25-
30,30-35,35-40 and >40; figure 3). The effect was similar when we used smoking as a 
covariate (table S10) and, as expected, was stronger when we used 7 variants that were 
individually associated with body fat percentage at p<3E-5 (table S11).  
We next used the genetic score for favorable adiposity and a genetic risk score for BMI in 
order to test the hypothesis that a general genetic predisposition to higher BMI interacted 
with a general predisposition to favorable adiposity. We did not investigate specific variants 
for interaction. There was no evidence of interaction between the genetic score of favorable 
adiposity alleles and the genetic score of 69 BMI alleles (Pinteraction >0.05). Despite being 
more overweight, carrying more favorable adiposity alleles than average reduced the risk of 
type 2 diabetes in the 50% of individuals most genetically predisposed to high BMI (OR: 
0.885 [0.813,0.965]; p=0.005; figure 4; table S12). These effects were consistent with those 
expected given additive effects of the alleles. 
A genetic score of 11 favorable adiposity variants was associated with lower risk of 
hypertension.  
Despite being associated with higher fat mass, each additional favourable adiposity weighted 
allele was associated with a 0.255 mmHg ([0.334,0.176]; p=2E-10) lower systolic blood 
pressure, 0.096 mmHg ([0.143,0.048]; p=7E-5) lower diastolic blood pressure and 0.982 OR 
([0.974,0.989]; p=3E-6) lower risk of hypertension in the UK Biobank (table 1). These 
associations were statistically stronger when meta-analysing the UK Biobank data with five 
additional studies (table S7). These effects meant that the 50% of people carrying the most 
favourable adiposity alleles had a 0.732 mmHg ([0.980,0.484]; p=7E-9) lower systolic blood 
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pressure, 0.292 mmHg ([0.440,0.144]; p=1E-4) lower diastolic blood pressure and 0.946 OR 
([0.923,0.969]; p=7E-6) lower risk of hypertension than the 50% of people carrying the 
fewest favourable adiposity alleles (figure 1b; table S8). Despite the dichotomised body fat 
distribution, these effects were consistent in men and women (table S9) and across 6 
different bands of BMI (<25,25-30,30-35,35-40 and >40; figure 3). These effects were 
similar when we used smoking as a covariate or when we excluded individuals on blood 
pressure medication (table S10). As expected, the effects were stronger when we used 7 
variants that were individually associated with body fat percentage at p<3E-5 (table S11). 
There was no evidence of interaction between the genetic score of favorable adiposity alleles 
and the genetic score of 69 BMI alleles on systolic or diastolic blood pressure or the risk of 
hypertension (Pinteraction = 0.1, 0.07 and 0.7 respectively). Despite being more overweight, 
carrying more favorable adiposity alleles than average reduced the risk of hypertension in the 
50% of individuals most genetically predisposed to high BMI (OR: 0.960 [0.927,0.994]; 
p=0.02) and lowered their average systolic blood pressure (-0.475 [-0.829,-0.121]; p=0.009) 
but had no detectable effect on diastolic blood pressure (figure 4; table S12). These effects 
were consistent with those expected given additive effects of the alleles. 
A Genetic score of 11 favorable adiposity variants was associated with lower risk of heart 
disease.  
Despite being associated with higher fat mass, each additional favourable adiposity weighted 
allele was associated with a 0.967 OR ([0.950,0.984]; p=1E-4) lower risk of heart disease in 
the UK Biobank (table 1). This association was consistent when meta-analysing the UK 
Biobank data with five additional studies (table S7). Based on the UK Biobank study, these 
effects meant that the 50% of people carrying the most favourable adiposity alleles had a 
0.942 OR ([0.892,0.994]; p=0.03) lower risk of heart disease (figure 1b; table S8). Despite 
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the dichotomised body fat distribution, these effects were consistent in men and women, 
although they did not reach p<0.05 in women, where there were fewer heart disease cases 
(table S8) These effects were similar when we used smoking as a covariate or when we 
considered only individuals with the history of heart attack as cases (table S10). The effects 
were stronger when we used 7 variants that were individually associated with body fat 
percentage at p<3E-5 (table S11). 
There was no evidence of interaction between the genetic score of favorable adiposity alleles 
and the genetic score of 69 BMI alleles (Pinteraction = 0.5). Carrying more favorable adiposity 
alleles than average in the genetically predisposed individuals to high BMI had no detectable 
effect on risk of heart disease (figure 4; table S12). 
Effects of favourable adiposity alleles on disease increase when correcting for BMI 
As expected given that the favourable adiposity genetic score is associated with higher BMI, 
when we corrected for BMI, associations with reduced disease risk strengthened (table S13). 
These results showed that, for a given BMI, the 50% of individuals carrying the most 
favourable adiposity alleles were at lower risk of type 2 diabetes (OR: 0.837 [0.784,0.894]; 
p=1E-7), hypertension (OR: 0.935 [0.911,0.958]; p=1E-7) and heart disease (OR:0.921 
[0.872,0.973]; p=0.003) and had lower blood pressure (systolic: -0.859 mmHg [-1.099,-
0.618]; p=3E-12 and diastolic: -0.394 mmHg [-0.534,-0.254]; p=4E-8). These effects were 
consistent in men and women.  
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Discussion 
We replicated with very high statistical confidence results from previous studies showing that 
in combination, 11 common genetic variants are associated with higher adiposity but lower 
risk of type 2 diabetes, hypertension and heart disease. In total we used 164,609 individuals 
from 6 studies including the UK Biobank and included 6,735, 82,512 and 8,881 individuals 
with type 2 diabetes, hypertension and heart disease, respectively. These studies had not 
contributed to previous GWA studies and so our study provides completely independent 
replication of an apparently paradoxical association – alleles associated with higher fat mass 
lower the risk of metabolic disease. Our analyses separated by sex provided further insight 
into the likely mechanisms underlying these apparently paradoxical associations. In women, 
the extra body fat conferred by the favorable adiposity genetic score was more likely to be in 
the lower body, as measured by a lower waist-hip ratio and especially larger hip 
circumference. In men however, the extra body fat conferred by the favorable adiposity 
genetic score was more likely to be in the upper body, as indicated by a higher waist 
circumference and waist-hip ratio.  Data from previous studies provides some further 
explanation for the apparently paradoxical association. For example, in combination, the 
favorable adiposity alleles are associated with higher subcutaneous to visceral adipose ratio 
(10) higher insulin sensitivity, higher hip circumference, and higher gynoid and leg fat mass 
(11).  This set of associations is consistent with the alleles labeled as favorable adiposity (or 
most of them) exerting their effects through a primary role in adipose tissue and fat storage 
capacity, although we cannot rule out mechanisms where insulin resistance is the primary 
starting point. 
Our data replicate previous associations but provide an important advance for several 
reasons. First, we provide further evidence that the “favorable adiposity” alleles are 
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associated predominantly with higher fat mass rather than any other aspect of BMI such as 
lean mass. This finding is consistent with previous studies (9-11) and important because it 
shows that the alleles associated with higher BMI are not protecting from disease through 
higher muscle mass. Instead our results confirm that the genetic score associated with lower 
disease risk is associated with higher adiposity. Second, our data of body fat mass and body 
fat percentage in 118,012 individuals indicate that the favourable adiposity effects are likely 
limited to seven of the eleven variants. Two of these variants, those in IRS1 and PPARG, are 
well known and lie near genes with a well-established role in insulin signalling and adipocyte 
differentiation respectively. Our study shows that the variants in or near LYPLAL1, PEPD, 
GRB14, ANKRD55, and FAM13A, all of which were associated with body fat percentage at p 
< 3E-5, are very strong candidates for a role in adipocyte biology, an interpretation consistent 
with the fact that two of these variants, those in LYPLAL1 and GRB14, were associated with 
waist hip ratio at genome wide significance in previous GWAS of waist-hip ratio (20). Third, 
we have quantified the effects of genetically higher BMI on disease in a very large population 
based study which means effects are relatively unbiased by disease ascertainment. Fourth, 
because we used a single very large population with individual level data available we were 
able to look for interactions between a genetic predisposition to higher BMI and favorable 
adiposity. We also found that the effects of the favorable adiposity variants on disease risk 
were similar across all bands of BMI. These interaction analyses, made feasible by the 
availability of individual level data in a single very large study, showed two things. First, that 
the favourable adiposity alleles reduce the risk of disease at all BMIs and at high and low 
genetic risk of obesity (based on alleles identified by the GIANT consortium). Second, that 
there is no evidence of a synergistic effect that means some individuals are at especially high 
or low genetic risk of adverse adiposity effects.  
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Our study had a number of limitations. First we do not know which molecular pathways lead 
to a favorable adiposity phenotype although the presence of variants near the PPARG and 
IRS1 genes point to known mechanisms (21-23). Second, the 11 variants only explain a very 
small proportion of body fat percentage and disease risk. Many other factors will influence 
the difference in disease risk between two individuals of the same BMI. However, our results 
show that higher fat storage capacity is a likely mechanism that improves metabolic health in 
the general population. Third, the study of individual variants suggests that those at ARL15 
and TET2 may not represent a favorable adiposity phenotype. The final variant, that in 
RSPO3, is associated with waist-hip ratio in previous GWAS studies and in the UK biobank 
(data not shown) but not with altered BMI or fat mass – and so may represent a simple 
redistribution of the same amount of body fat. The signal at PDGFC may have a very subtle 
effect and needs further investigation. A further limitation is that we have not examined 
whether or not the variants alter adipocyte cell size or related features of adipocyte “function” 
and future studies are needed to examine features of adipocytes in tissue biopsies from 
individuals carrying many favourable adiposity alleles. 
In summary, the strong association between the favorable adiposity genetic score and body 
fat percentage and lower risk of cardiometabolic diseases regardless of BMI or high genetic 
predisposition to obesity suggests that the mechanism of disease protection is an increased 
capacity to store triglyceride subcutaneously. The explanation most compatible with our 
findings is that the increased adipose storage capacity is in the lower body in women, but the 
upper body in men. Individuals who have genetically higher fat storage capacity can stay 
metabolically healthier at higher BMIs than individuals without such genetic variation, 
thereby partially explaining the concept of individual BMI thresholds to develop metabolic 
disease.   
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Figure legends 
Figure 1. The effect of favourable adiposity on measures of adiposity and cardiometabolic 
disease risk in the UK Biobank study. Effects are given by comparing the 50% of people 
carrying the most favourable adiposity alleles with the 50% of people carrying the fewest 
favourable adiposity alleles. The error bars indicate 95% confidence intervals. All models 
were adjusted for age, sex, genotyping array, study center and within UK principle 
components.  
Figure 2. The effect of favourable adiposity on measures of body distribution including waist 
circumference, hip circumference and waist-hip ratio separated by sex. Effects are per 
additional weighted copy of the adiposity increasing allele. All models were adjusted for age, 
sex, genotyping array, study center and principle components where applicable. 
Figure 3. The effect of favourable adiposity on measures of adiposity and cardiometabolic 
disease risk in the UK Biobank study in all individuals and in individuals split into BMI 
categories. Effects are given by comparing the 50% of people carrying the most favourable 
adiposity alleles with the 50% of people carrying the fewest favourable adiposity alleles in all 
individuals and within BMI strata. The error bars indicate 95% confidence intervals. All 
models were adjusted for age, sex, genotyping array, study center and within UK principle 
components. 
Figure 4. The combined effect of favorable adiposity and BMI genetic scores on 
cardiometabolic disease risk. We grouped the UK Biobank individuals based on the median 
of the two genetic score distributions: (i) low BMI – high FA: individuals with below median 
BMI genetic score and above median favorable adiposity genetic score, (ii) low BMI – low 
FA: individuals with below median BMI genetic score and below median favorable adiposity 
genetic score, (iii) high BMI – high FA: individuals with above median BMI genetic score 
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and above median favorable adiposity genetic score and (iv) high BMI – low FA: individuals 
with above median BMI genetic score and below median favorable adiposity genetic score. 
The error bars indicate 95% confidence intervals. 
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Table 1. The effect of a favourable adiposity genetic score on measures of adiposity and 
cardiometabolic disease risk in the UK Biobank study. Effects are given per carrying 
additional adiposity increasing weighted allele. LCI: Lower confidence interval; UCI: 
Upper confidence interval; P: p-value; N: total sample size. 
 
Outcome Effect size LCI UCI P N 
Body fat percentage 
(%) 
0.126 0.104 0.149 8E-28 118,012 
BMI (Kg/m
2
) 0.046 0.029 0.063 2E-7 119,688 
Body fat mass (Kg) 0.156 0.123 0.190 3E-18 118,024 
Body fat-free mass 
(Kg) 
-0.030 -0.053 -0.007 0.01 118,221 
Height (cm) 0.006 -0.017 0.028 0.6 120,084 
Type 2 diabetes (OR) 0.943 0.924 0.963 2E-8 4,003 vs. 113,203 
Systolic blood pressure 
(mmHg) 
-0.255 -0.334 -0.176 2E-10 120,008 
Diastolic blood 
pressure (mmHg) 
-0.096 -0.143 -0.048 7E-5 119,821 
Hypertension (OR) 0.982 0.974 0.989 3E-6 65,584 vs. 53,377 
Heart disease (OR) 0.967 0.950 0.984 1E-4 5,758 vs. 113,930 
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 Table S1. Summary characteristics of participating studies. 
Variable Statistics UK Biobank EXTEND Generation Scotland GoDARTS PROSPER  EPIC-Norfolk 
Age 
N  
mean [min to max] (sd) 
120286 
 56.92 [40 to 73] 
(7.94) 
6504  
56.51 [18 to 98 
] (15.11) 
14064  
48.58 [18 to 99] (15.07) 
4086  
60.23 [30.78 to 
92.28] (11.45) 
5244  
75.34 [70 to 
83.39] (3.35) 
20855 
59.15 [39.49 to 
79.08] (9.27) 
Sex males / females 56936 / 63350 2772 / 3732 5784 / 8280 2107 / 1979 2524 / 2720 9,699 / 11,156 
BMI (kg m-2) 
N  
mean [min to max] (sd) 
119688  
27.53 [12.12 to 
74.68] (4.82) 
6493  
27.34 [14.27 to 
63.37 ] (5.22) 
13968  
26.87 [13.16 to 71.35] 
(5.42) 
4085  
27.44 [14.3 to 
59.8] (4.79) 
5244  
26.82 [15.24 to 
50.08] (4.18) 
20825 
26.29 [15.23 to 
58.70] (3.82) 
Body fat 
percentage 
N  
mean [min to max] (sd) 
118012  
31.44 [6.92 to 
69.79] (8.5) 
5969  
31.83 [1.2 to 58 
] (8.67) 
13668  
30.23 [1 to 62] (9.68) 
NA NA 
13422 
32.34 [1.5 to 
98.5] (11.19) 
Type 2 diabetes N cases / N controls 4040 / 113735 1505 / 5444 477 / 13551 327 / 3759 544 / 4700 1,347 / 19,508 
Systolic blood 
pressure (mmHg) 
N  
mean [min to max] (sd) 
120008  
144.87 [72 to 252.5] 
(24.13) 
6503  
136.07 [84 to 
234 ] (20.89) 
14041  
133.25 [74 to 239] 
(19.27) 
4081  
142.27 [85 to 
237.5] (22.36) 
5220  
163.66 [76 to 
235] (24.05) 
20817 
138.05 [88 to 
235] (20.09) 
Diastolic blood 
pressure (mmHg) 
N  
mean [min to max] (sd) 
119821  
86.65 [40 to 147] 
(13.58) 
6503  
79.57 [47 to 
131 ] (11.19) 
14041  
80.58 [42 to 145] 
(10.98) 
4081  
83.64 [46.5 to 
129.5] (11.07) 
5220  
89.65 [47 to 129] 
(12.8) 
20817 
84.32 [46.5 to 
189] (12.18) 
Hypertension N cases / N controls 65,976 / 53,567 1718 / 5460 2056 / 11972 1774 / 2307 3257 / 1987 9,449 / 11,406 
Heart disease N cases / N controls 5807 / 114479 509 / 6669 571 / 13457 NA 2034 / 3210 1,369 / 19,486 
PLD risk score 
N  
mean [min to max] (sd) 
120286  
9.77 [2.91 to 15.45] 
(1.57) 
6268  
9.32 [2 to 13.94 
] (1.51) 
8226  
10.22 [3.82 to 15.45] 
(1.52) 
4086  
9.76 [4.23 to 
14.56] (1.61) 
5244  
9.79 [4.25 to 
14.82] (1.57) 
20855 
9.77 [3.62 to 
15.34] (1.58) 
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 Table S2. Eleven variants associated with favorable adiposity. Weights are from the most recent meta-analysis of Glucose and Insulin 
Consortium (MAGIC) genome wide association studies normalized based on the variant at PPARG. The genotype information is for the UK 
Biobank study. MAF: Minor allele frequency. 
SNP Notable gene(s) MAF 
Adiposity 
increasing allele 
Other allele Directly genotyped/imputed Imputation r2 Weights 
rs459193 ANKRD55-MAP3K1 0.27 A G imputed 1.00 0.69 
rs4865796 ARL15 0.33 G A imputed 1.00 0.73 
rs3822072 FAM13A 0.48 G A imputed 1.00 0.55 
rs10195252 GRB14 0.40 C T imputed 1.00 0.82 
rs2943645 IRS1 0.37 C T imputed 1.00 0.91 
rs4846565 LYPLAL1 0.33 A G imputed 1.00 0.62 
rs6822892 PDGFC 0.32 G A imputed 1.00 0.65 
rs731839 PEPD 0.34 A G imputed 1.00 0.7 
rs17036328 PPARG 0.14 C T imputed 1.00 1 
rs2745353 RSPO3 0.49 C T imputed 1.00 0.67 
rs974801 TET2 0.38 A G imputed 1.00 0.66 
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 Table S3. Genetic variant previously identified to be associated with BMI in genome wide association studies. The genotype information is for the 
UK Biobank study. 
SNP 
Notable 
gene(s) 
Excluded Reason for exclusion 
BMI increasing 
allele 
Other 
allele 
Directly genotyped/imputed Imputation r2 
rs1000940 RABEP1 No  NA G A Imputed 1.00 
rs10132280 STXBP6 No  NA C A Imputed 0.97 
rs1016287 FLJ30838 No  NA T C Imputed 0.99 
rs10182181 ADCY3 No  NA G A Imputed 1.00 
rs10733682 LMX1B No  NA A G Imputed 0.96 
rs10938397 GNPDA2 No  NA G A Directly genotyped NA 
rs10968576 LINGO2 No  NA G A Directly genotyped NA 
rs11030104 BDNF Yes 
BMI-raising allele also 
associated with regular 
smoking (which itself has a 
causal effect on BMI in 
opposite direction) 
A G NA NA 
rs11057405 CLIP1 No  NA G A Directly genotyped NA 
rs11126666 KCNK3 No  NA A G Imputed 0.99 
rs11165643 PTBP2 No  NA T C Imputed 1.00 
rs11191560 NT5C2 No  NA C T Imputed 1.00 
rs11583200 ELAVL4 No  NA C T Imputed 0.99 
rs1167827 HIP1 No  SNP not in HWE G A Directly genotyped NA 
rs11688816 EHBP1 No  NA G A Imputed 0.98 
rs11727676 HHIP No  NA T C Directly genotyped NA 
rs11847697 PRKD1 No  NA T C Directly genotyped NA 
rs12286929 CADM1 No  NA G A Imputed 0.99 
rs12401738 FUBP1 No  NA A G Imputed 1.00 
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 rs12429545 OLFM4 No  NA A G Imputed 0.98 
rs12446632 GPRC5B No  NA G A Imputed 1.00 
rs12566985 
FPGT-
TNNI3K 
No  NA G A Imputed 0.99 
rs12885454 PRKD1 No  NA C A Imputed 1.00 
rs12940622 RPTOR No  NA G A Imputed 1.00 
rs13021737 TMEM18 No  NA G A Imputed 0.99 
rs13078960 CADM2 No  NA G T Imputed 0.99 
rs13107325 SLC39A8 Yes 
Missense Ala/Thr 
polymorphism located in exon 
7 of SLC39A8, which encodes 
a zinc transporter that also 
transports cadmium and 
manganese. It is also 
associated with BP and HDL 
levels, and presumably these 
and the BMI effect are 
secondary to the metal ion 
transport variation. 
T C NA NA 
rs13191362 PARK2 No  NA A G Imputed 0.99 
rs1516725 ETV5 No  NA C T Imputed 0.99 
rs1528435 UBE2E3 No  NA T C Imputed 1.00 
rs1558902 FTO No  NA A T Imputed 1.00 
rs16851483 RASA2 No  NA T G Imputed 1.00 
rs16951275 MAP2K5 No  NA T C Imputed 1.00 
rs17001654 SCARB2 Yes SNP not in HWE G C NA NA 
rs17024393 GNAT2 No  NA C T Imputed 0.99 
rs17094222 HIF1AN No  NA C T Imputed 0.97 
rs17405819 HNF4G No  NA T C Imputed 1.00 
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 rs17724992 PGPEP1 No  NA A G Imputed 0.98 
rs1808579 C18orf8 No  NA C T Imputed 1.00 
rs1928295 TLR4 No  NA T C Imputed 1.00 
rs2033529 TDRG1 Yes SNP not available G A NA NA 
rs2033732 RALYL No  NA C T Directly genotyped NA 
rs205262 C6orf106 No  NA G A Imputed 1.00 
rs2075650 TOMM40 No  SNP not in HWE A G Imputed 0.99 
rs2112347 POC5 No  NA T G Directly genotyped NA 
rs2121279 LRP1B No  NA T C Imputed 0.99 
rs2176598 HSD17B12 No  NA T C Directly genotyped NA 
rs2207139 TFAP2B No  NA G A Imputed 1.00 
rs2245368 PMS2L11 No  NA C T Directly genotyped NA 
rs2287019 QPCTL No  NA C T Imputed 0.98 
rs2365389 FHIT No  NA C T Imputed 0.99 
rs2650492 SBK1 No  NA A G Imputed 0.98 
rs2820292 NAV1 No  NA C A Directly genotyped NA 
rs29941 KCTD15 No  NA G A Directly genotyped NA 
rs3101336 NEGR1 No  NA C T Directly genotyped NA 
rs3736485 DMXL2 No  NA A G Imputed 0.99 
rs3810291 ZC3H4 No  NA A G Directly genotyped NA 
rs3817334 MTCH2 No  NA T C Directly genotyped NA 
rs3849570 GBE1 No  NA A C Imputed 1.00 
rs3888190 ATP2A1 Yes 
Associated with lots of other 
traits and is a big haplotype 
A C NA NA 
rs4256980 TRIM66 No  NA G C Imputed 0.99 
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 rs4740619 C9orf93 No  NA T C Imputed 1.00 
rs543874 SEC16B No  NA G A Directly genotyped NA 
rs6477694 EPB41L4B No  NA C T Imputed 0.99 
rs6567160 MC4R No  NA C T Imputed 1.00 
rs657452 AGBL4 No  NA A G Imputed 0.99 
rs6804842 RARB No  NA G A Imputed 0.99 
rs7138803 BCDIN3D No  NA A G Directly genotyped NA 
rs7141420 NRXN3 No  NA T C Imputed 0.98 
rs7243357 GRP No  NA T G Imputed 0.99 
rs758747 NLRC3 No  NA T C Imputed 0.97 
rs7599312 ERBB4 No  NA G A Imputed 0.97 
rs7899106 GRID1 No  NA G A Imputed 0.99 
rs9400239 FOXO3 No  NA C T Imputed 0.99 
rs9581854 MTIF3 No  NA T C Imputed 0.99 
rs9925964 KAT8 No  NA A G Directly genotyped NA 
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 Table S4. Details of genotyping/imputation methods used by each study. 
 
Which SNPs 
were 
directly 
genotyped? 
Which SNPs 
 were 
imputed? 
Imputation  
software 
Reference  
panel 
Imputation  
Quality 
Genotyping  
platform 
Genotyping  
centre 
Genotyping  
calling 
algorithm 
Call rate HWE 
EXTEND ALL NA NA NA NA KASP 
LGC, Queens 
Road, 
Teddington, 
Middlesex, 
TW11 0LY, UK 
NA > 99% > 0.05 
Generation 
Scotland 
rs17367504, 
rs3753584, 
rs213765, 
rs1238, 
rs2932538, 
rs9425291, 
rs1044299, 
rs2605096, 
rs1572505, 
rs12999687, 
rs1260326, 
rs13408002, 
rs2540950, 
rs2249105, 
rs4988235, 
rs182549, 
rs7592412, 
rs3769877, 
rs2943645, 
rs2972143, 
rs6766610, 
rs9863261, 
rs160208, 
rs17036328, 
rs2197423, 
rs633185, 
rs11953630, 
rs2521501, 
rs6912327, 
rs17169104, 
rs1725074, 
rs6581104, 
rs2710322, 
rs6061036, 
rs1530559, 
rs2822383, 
rs8129930, 
rs6574629, 
rs34106, 
rs6664203, 
rs12125782, 
rs9394279 
SHAPEIT 
and 
IMPUTE2 
1000G 
Version 3 
RSQ>0.4 
Illumina 
HumanOmniEx
pressExome-
8v1_A 
Edinburgh 
Wellcome 
Trust Clinical 
Research 
Facility 
Genome 
Studio 
>=0.98 >1e-6 
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 rs2455800, 
rs1496653, 
rs13096477, 
rs3774372, 
rs1994157, 
rs11708451, 
rs5012971, 
rs699469, 
rs11626, 
rs11708067, 
rs6798189, 
rs3103760, 
rs1918966, 
rs13130484, 
rs12641981, 
rs1458038, 
rs9991328, 
rs13107325, 
rs974801, 
rs17019341, 
rs10517621, 
rs6855363, 
rs1425486, 
rs12498968, 
rs31888, 
rs702634, 
rs4865796, 
rs2306520, 
rs458036, 
rs7703560, 
rs7719763, 
rs9368222, 
rs1799945, 
rs129128, 
rs805303, 
rs644827, 
rs644774, 
rs9267803, 
rs4713506, 
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 rs10947465, 
rs7763695, 
rs12525532, 
rs7758272, 
rs7762809, 
rs4715554, 
rs7759938, 
rs314286, 
rs7766106, 
rs632057, 
rs668459, 
rs2782527, 
rs474513, 
rs539298, 
rs3801033, 
rs4721400, 
rs10282436, 
rs1004558, 
rs7811653, 
rs2108349, 
rs7953, 
rs13234407, 
rs983309, 
rs930991, 
rs2572432, 
rs4841600, 
rs4474021, 
rs11783903, 
rs2737219, 
rs2721939, 
rs894344, 
rs10116772, 
rs6476842, 
rs907076, 
rs1033056, 
rs10968576, 
rs10968577, 
rs4319185, 
rs2810726, 
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 rs11596960, 
rs11014171, 
rs9325886, 
rs17785945, 
rs7922049, 
rs10761785, 
rs10822181, 
rs10887766, 
rs10788575, 
rs5015480, 
rs10786152, 
rs17114803, 
rs12221064, 
rs7903146, 
rs4132670, 
rs896043, 
rs381815, 
rs11231693, 
rs562590, 
rs4980786, 
rs534668, 
rs10830963, 
rs7970953, 
rs7132434, 
rs11171710, 
rs12371967, 
rs11105328, 
rs855213, 
rs10850411, 
rs7970903, 
rs10846580, 
rs863750, 
rs1360485, 
rs1045411, 
rs9574557, 
rs17109256, 
rs8026338, 
rs1378940, 
rs3810813, 
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 rs4598913, 
rs7192726, 
rs9939973, 
rs1121980, 
rs11078685, 
rs4925108, 
rs17608766, 
rs11874, 
rs12952581, 
rs12454712, 
rs4804833, 
rs731839, 
rs12481037, 
rs6072279, 
rs6026728, 
rs132985, 
rs133021 
GoDARTS 
Combination of 
directly 
genotyped and 
imputed dosages 
for all variants. 
 
NA NA NA 
Affymetrics, 
Illumina  
NA NA > 99% 
> 
0.001 
Table S5. Association between 11 favorable adiposity variants and body fat percentage in the UK Biobank study. LCI: Lower confidence interval; 
UCI: Upper confidence interval; P: p-value; N: total sample size. 
OUTCOME LOCI BETA LCI UCI P N 
Body fat percentage LYPLAL1 0.176 0.123 0.228 7E-11 118012 
Body fat percentage PPARG 0.251 0.174 0.328 2E-10 118012 
Body fat percentage PEPD 0.148 0.094 0.201 6E-8 118012 
Body fat percentage GRB14 0.128 0.077 0.180 9E-7 118012 
Body fat percentage IRS1 0.123 0.070 0.175 5E-6 118012 
Body fat percentage ANKRD55 0.125 0.067 0.183 2E-5 118012 
Body fat percentage FAM13A 0.108 0.057 0.158 E-5 118012 
rs4846565, 
rs10195252, 
rs2943645, 
rs974801 
rs17036328, 
rs3822072, 
rs6822892, 
rs459193, 
rs4865796, 
rs2745353, 
rs731839, 
rs9939609 
MACH 
Hapmap 
built II 
release 23 
excellent, all 
SNPs had 
MACH-Rsq > 
0.95 
Illumina 660-
Quad 
beadchips 
Erasmus MC 
Rotterdam, the 
Netherlands 
Illumina 
Genestudio 
> 0.975 > 1E-6 
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 PROSPER  
Body fat percentage
Body fat percentage
Body fat percentage
Body fat percentage
EPIC 
All but 
rs6536208 
rs6536208 
IMPUTE 
2.3.1 
1000 
Genomes 
v3 
NA 
UKBiobank 
Axiom 
U.CAM 
Pathology & 
Affymetrix 
Axiom GT1 > 0.95 > 1E-8 
 
 
Table S6. Association between the favorable adiposity genetic scores and waist-hip ratio, waist circumference and hip circumference in 
the UK Biobank study. LCI: Lower confidence interval; UCI: Upper confidence interval; P: p-value; N: total sample size. 
Genetic score Trait Sex Beta LCI UCI P N 
P-heterogeneity 
between sexes 
11 SNPs Waist-hip ratio All -0.0006 -0.0009 -0.0004 1E-7 120095 
3E-18 11 SNPs Waist-hip ratio Men 0.0005 0.0002 0.0009 0.001 56849 
11 SNPs Waist-hip ratio Women -0.0017 -0.0021 -0.0014 9E-23 63246 
11 SNPs Waist All 0.0607 0.0175 0.1038 0.006 120121 
1E-6 11 SNPs Waist Men 0.1726 0.1131 0.2320 1E-8 56865 
11 SNPs Waist Women -0.0398 -0.1019 0.0223 0.2 63256 
11 SNPs Hip All 0.1400 0.1068 0.1733 2E-16 120112 
0.2 11 SNPs Hip Men 0.1178 0.0776 0.1581 1E-8 56859 
11 SNPs Hip Women 0.1607 0.1090 0.2125 1E-9 63253 
7 SNPs Waist-hip ratio All -0.0003 -0.0006 -2E-06 0.05 120095 
7E-14 7 SNPs Waist-hip ratio Men 0.0009 0.0005 0.0014 5E-6 56849 
7 SNPs Waist-hip ratio Women -0.0014 -0.0018 -0.0010 3E-11 63246 
7 SNPs Waist All 0.1251 0.0722 0.1779 4E-6 120121 0.0001 
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Table S7. The effect of the favorable adiposity genetic score on measures of adiposity and cardiometabolic disease risk. Results are from the 
meta-analysis of 6 studies. NA: not available; LCI: lower confidence interval; UCI: upper confidence interval. Effects are per additional weighted 
copy of the adiposity increasing allele. 
TRAIT BETA/OR LCI UCI P N P-heterogeneity 
Body fat percentage 0.124 0.103 0.145 8.00E-31 145,187 0.7 
BMI 0.043 0.029 0.057 3 E-09 164,274 0.4 
Type 2 diabetes 0.937 0.952 0.923 5.00E-17 6,735 vs. 155,253 0.6 
Systolic blood pressure -0.251 -0.315 -0.187 2.00E-14 164,609 0.9 
Diastolic blood pressure -0.107 -0.146 -0.068 7.00E-08 164,422 0.6 
Hypertension 0.981 0.988 0.975 3.00E-08 82,512 vs. 81,239 0.5 
Heart disease 0.973 0.987 0.96 1.00E-04 8,881 vs. 151,532 0.4 
 
 
  
7 SNPs Waist Men 0.2346 0.1618 0.3073 3E-10 56865 
7 SNPs Waist Women 0.0269 -0.0492 0.1031 0.5 63256 
7 SNPs Hip All 0.1728 0.1320 0.2135 9E-17 120112 
0.09 7 SNPs Hip Men 0.1374 0.0882 0.1867 5E-8 56859 
7 SNPs Hip Women 0.2060 0.1426 0.2694 2E-10 63253 
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 Table S8. The effect of favourable adiposity on measures of adiposity and cardiometabolic disease risk in the UK Biobank study. Effects are given by 
comparing the 50% of people carrying the most favourable adiposity alleles with the 50% of people carrying the fewest favourable adiposity alleles. 
NA: not available; LCI: lower confidence interval; UCI: upper confidence interval. Effects are per additional weighted copy of the adiposity increasing 
allele. 
OUTCOME BETA/OR  LCI  UCI  P 
Body fat percentage 0.301 0.230 0.372 1E-16 
BMI 0.120 0.066 0.174 0.00001 
Body fat mass 0.397 0.291 0.503 2E-13 
body fat-free mass -0.036 -0.109 0.036 0.3 
Type 2 diabetes 0.895 0.840 0.954 0.0006 
Systolic blood pressure -0.732 -0.980 -0.484 7E-9 
Diastolic blood pressure -0.292 -0.440 -0.144 0.0001 
Hypertension 0.946 0.923 0.969 7E-6 
Heart disease 0.942 0.892 0.994 0.03 
 
 
 
  
Page 51 of 58 Diabetes
 Table S9. Within sex effect of 11 favorable adiposity genetic score on measures of adiposity and cardiometabolic disease risk in the UK Biobank 
study. Effects are per additional weighted copy of the adiposity increasing allele. LCI: Lower confidence interval; UCI: Upper confidence interval; 
P: p-value; N: total sample size. 
 
Men Women 
 
OUTCOME BETA/OR LCI UCI P N BETA/OR LCI UCI P N P-heterogeneity 
Body fat 
percentage 
0.158 0.129 0.188 2.00E-25 55667 0.098 0.065 0.132 1.00E-08 62345 0.03 
BMI 0.057 0.034 0.079 8.00E-07 56668 0.037 0.011 0.063 0.005 63020 0.5 
Body fat mass 0.190 0.146 0.233 2.00E-17 55679 0.128 0.077 0.178 7.00E-07 62345 0.2 
body fat-free 
mass 
-0.049 -0.090 -0.009 0.02 55861 -0.013 -0.038 0.012 0.3 62360 0.3 
Type 2 diabetes 0.940 0.917 0.964 1.00E-06 
2,686 vs. 
52,598 
0.949 0.916 0.983 0.003 
1,317 vs. 
60,605 
0.9 
Systolic blood 
pressure 
-0.278 -0.391 -0.165 1.00E-06 56830 -0.237 -0.347 -0.127 0.00002 62856 0.9 
Diastolic blood 
pressure 
-0.104 -0.173 -0.035 0.003 56765 -0.088 -0.153 -0.024 0.007 62736 0.9 
Hypertension 0.982 0.971 0.993 0.001 
35,634 vs. 
20,680 
0.982 0.971 0.992 0.0006 
29,950 vs. 
32,697 
1.0 
Heart disease 0.963 0.944 0.983 0.0004 
4,169 vs. 
52,499 
0.975 0.944 1.006 0.1 
1,589 vs. 
61,431 
0.8 
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 Table S10. Sensitivity analysis of the effect of a favourable adiposity genetic score on cardiometabolic disease risk 
in the UK Biobank study. NA: not available; LCI: lower confidence interval; UCI: upper confidence interval. Effects 
are per additional weighted copy of the adiposity increasing allele. 
OUTCOME BETA/OR LCI UCI P N 
Systolic blood pressure 
(excluding those on blood pressure medication) 
-0.139  -0.208 -0.069  0.00009  93443 
Diastolic blood pressure 
(excluding those on blood pressure medication) 
-0.030 -0.070 0.010 0.1 93289 
Heart disease  
(those with heart attack as cases) 
0.979 0.949 1.009 0.2 2,180 vs. 113,930 
Type 2 diabetes  
(corrected for smoking) 
0.944 0.925 0.964 4.00E-08 3,988 vs. 112,172 
Systolic blood pressure 
(corrected for smoking) 
-0.253 -0.332 -0.173 4.00E-10 118360 
Diastolic blood pressure 
(corrected for smoking) 
-0.096 -0.143 -0.048 0.00007 118173 
Hypertension  
(corrected for smoking) 
0.982 0.974 0.990 6.00E-06 65,080 vs. 52,827 
Heart disease 
(corrected for smoking) 
0.968 0.951 0.985 0.0002 5,684 vs. 112,950 
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 Table S11. The effect of a favourable adiposity genetic score (using 7 SNPs associated with body fat percentage at p < 3E-5) on measures of 
adiposity and cardiometabolic disease risk in the UK Biobank study. LCI: lower confidence interval; UCI: upper confidence interval. Effects are 
per additional weighted copy of the adiposity increasing allele. 
OUTCOME BETA/OR  LCI  UCI  P N 
Body fat percentage 0.190 0.162 0.217 4.82E-41 118012 
BMI 0.061 0.040 0.082 1.219E-08 119688 
Body fat mass 0.237 0.195 0.278 2.63E-29 118221 
body fat-free mass -0.031 -0.059 -0.002 0.03294344 118024 
Type 2 diabetes 0.914 0.891 0.937 1.301E-12 4,003 vs. 113,203 
Systolic blood pressure -0.349 -0.446 -0.252 1.50E-12 120008 
Diastolic blood pressure -0.123 -0.181 -0.065 0.00002907 119821 
Hypertension 0.975 0.965 0.984 1.09E-07 65,584 vs. 53,377 
Heart disease 0.954 0.934 0.975 0.0000143 5,758 vs. 113,930 
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 Table S12. The effect of genetic predisposition to favorable adiposity and BMI on risk of cardiometabolic disease outcomes. Effects are 
calculated comparing to the reference group in the UK Biobank study. LCI: Lower confidence interval; UCI: Upper confidence interval; P: p-
value; N: total sample size. 
Trait/disease Category BMIs mean (SD) BETA/OR LCI UCI P  
Type 2 diabetes High BMI Low FA 27.84 (4.9) 1.418 1.296 1.553 3.00E-14 
Type 2 diabetes High BMI High FA 28.04 (5.1) 1.255 1.151 1.368 2.00E-07 
Type 2 diabetes Low BMI Low FA 27.08 (4.6) 1.119 1.018 1.231 0.02 
Type 2 diabetes Low BMI High FA 27.13 (4.6) reference reference reference reference 
Systolic blood pressure High BMI Low FA 27.84 (4.9) 1.495 1.140 1.849 1.00E-16 
Systolic blood pressure High BMI High FA 28.04 (5.1) 1.019 0.690 1.347 1.00E-09 
Systolic blood pressure Low BMI Low FA 27.08 (4.6) 0.724 0.370 1.078 0.00006 
Systolic blood pressure Low BMI High FA 27.13 (4.6) reference reference reference reference 
Diastolic blood pressure High BMI Low FA 27.84 (4.9) 0.839 0.628 1.051 7.00E-15 
Diastolic blood pressure High BMI High FA 28.04 (5.1) 0.676 0.480 0.872 1.00E-11 
Diastolic blood pressure Low BMI Low FA 27.08 (4.6) 0.253 0.042 0.464 0.02 
Diastolic blood pressure Low BMI High FA 27.13 (4.6) reference reference reference reference 
Hypertension High BMI Low FA 27.84 (4.9) 1.128 1.090 1.168 1.00E-11 
Hypertension High BMI High FA 28.04 (5.1) 1.084 1.049 1.119 1.00E-06 
Hypertension Low BMI Low FA 27.08 (4.6) 1.050 1.014 1.087 0.006 
Hypertension Low BMI High FA 27.13 (4.6) reference reference reference reference 
Heart disease High BMI Low FA 27.84 (4.9) 1.101 1.019 1.190 0.02 
Heart disease High BMI High FA 28.04 (5.1) 1.092 1.016 1.173 0.02 
Heart disease Low BMI Low FA 27.08 (4.6) 1.042 0.964 1.127 0.3 
Heart disease Low BMI High FA 27.13 (4.6) reference reference reference reference 
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 Table S13. The effect of genetic predisposition to favorable adiposity on risk of cardiometabolic disease outcomes 
using adiposity traits as covariates to test if they are mediators. Effects are per additional weighted copy of the 
adiposity increasing allele in the UK Biobank study. LCI: Lower confidence interval; UCI: Upper confidence interval; 
P: p-value; N: total sample size. 
OUTCOME COVARIAT SEX BETA/OR LCI UCI P N 
Type 2 diabetes 
 
None 
Males 
 
0.908 0.873 0.944 1E-6 55492 
Body fat percentage 0.854 0.820 0.890 5E-14 54286 
BMI 0.871 0.836 0.907 3E-11 55239 
Waist 0.869 0.834 0.905 1E-11 55427 
Waist-hip ratio 0.886 0.851 0.923 4E-9 55411 
None 
Females 
 
0.921 0.872 0.973 0.003 62196 
Body fat percentage 0.889 0.840 0.940 4E-5 61221 
BMI 0.889 0.840 0.941 4E-5 61881 
Waist 0.898 0.848 0.950 2E-4 62109 
Waist-hip ratio 0.940 0.888 0.994 0.03 62099 
Systolic blood pressure 
 
None 
Males 
 
-0.020 -0.028 -0.012 1E-6 56830 
Body fat percentage -0.030 -0.038 -0.022 2E-13 55580 
BMI -0.025 -0.033 -0.017 1E-9 56572 
Waist -0.025 -0.033 -0.017 5E-10 56767 
Waist-hip ratio -0.023 -0.031 -0.015 2E-08 56752 
None 
Females 
 
-0.017 -0.025 -0.009 2E-4 63178 
Body fat percentage -0.022 -0.030 -0.015 9E-09 62185 
BMI -0.019 -0.026 -0.011 1E-06 62856 
Waist -0.015 -0.022 -0.007 1E-4 63092 
Waist-hip ratio -0.009 -0.017 -0.002 0.01 63082 
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Diastolic blood pressure 
None 
Males 
-0.012 -0.020 -0.004 0.005 56765 
Body fat percentage -0.025 -0.033 -0.018 3E-10 55514 
BMI -0.018 -0.025 -0.010 1E-5 56508 
Waist -0.019 -0.027 -0.011 3E-6 56702 
Waist-hip ratio -0.016 -0.024 -0.008 1E-4 56687 
None 
Females 
 
-0.011 -0.019 -0.003 0.007 63056 
Body fat percentage -0.018 -0.026 -0.011 1E-6 62064 
BMI -0.013 -0.020 -0.005 6E-4 62736 
Waist -0.008 -0.015 0.000 0.05 62970 
Waist-hip ratio -0.001 -0.009 0.007 0.8 62960 
Hypertension 
None 
Males 
 
0.971 0.954 0.989 0.001 56549 
Body fat percentage 0.951 0.933 0.968 9E-8 55303 
BMI 0.963 0.945 0.981 6E-5 56289 
Waist 0.961 0.943 0.978 2E-5 56484 
Waist-hip ratio 0.965 0.948 0.983 1E-4 56469 
None 
Females 
 
0.971 0.955 0.988 6E-4 62955 
Body fat percentage 0.959 0.943 0.976 2E-6 61967 
BMI 0.967 0.950 0.984 1E-4 62634 
Waist 0.975 0.958 0.992 0.004 62869 
Waist-hip ratio 0.987 0.970 1.003 0.1 62859 
Heart disease 
None 
Males 
 
0.943 0.913 0.974 4E-4 56936 
Body fat percentage 0.924 0.894 0.955 4E-6 55667 
BMI 0.930 0.900 0.961 1E-5 56668 
Waist 0.931 0.901 0.962 1E-5 56865 
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 Waist-hip ratio 0.936 0.906 0.967 7E-5 56849 
None 
Females 
 
0.960 0.913 1.010 0.1 63201 
Body fat percentage 0.940 0.893 0.990 0.02 62199 
BMI 0.956 0.909 1.006 0.08 62872 
Waist 0.961 0.914 1.011 0.1 63108 
Waist-hip ratio 0.978 0.930 1.029 0.4 63098 
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